Analyzing Q Biomed (OTCMKTS:QBIO) and Concentra Group Holdings Parent (NYSE:CON)

Concentra Group Holdings Parent (NYSE:CON) and Q Biomed (OTCMKTS:QBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Profitability

This table compares Concentra Group Holdings Parent and Q Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concentra Group Holdings Parent	7.97%	47.14%	6.48%
Q Biomed	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Concentra Group Holdings Parent and Q Biomed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concentra Group Holdings Parent	0	1	7	0	2.88
Q Biomed	0	0	0	0	0.00

Concentra Group Holdings Parent currently has a consensus target price of $30.20, indicating a potential downside of 5.09%. Given Q Biomed’s higher probable upside, analysts clearly believe Q Biomed is more favorable than Concentra Group Holdings Parent.

Earnings & Valuation

This table compares Concentra Group Holdings Parent and Q Biomed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concentra Group Holdings Parent	$2.16 billion	1.88	$166.41 million	$1.39	22.89
Q Biomed	N/A	N/A	N/A	($0.02)	N/A

Concentra Group Holdings Parent has higher revenue and earnings than Q Biomed. Q Biomed is trading at a lower price-to-earnings ratio than Concentra Group Holdings Parent, indicating that it is currently the more affordable of the two stocks.

Summary

Concentra Group Holdings Parent beats Q Biomed on 7 of the 8 factors compared between the two stocks.

About Concentra Group Holdings Parent

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.